NeuroEM

02/02/2026

ICYMI: Dr. W. Scott Burgin has joined NeuroEM as Chief Medical Officer, bringing what CEO Chuck Papageorgiou calls a "rare combination of clinical excellence, scientific rigor, and entrepreneurial vision [that] aligns perfectly with our mission to advance transformative neurological care." https://ow.ly/OCxt50Y6G9t

01/31/2026

In a move that marks an exciting and important milestone for NeuroEM, the company announced today the appointment of Dr. W. Scott Burgin as Chief Medical Officer. His decades of leadership in stroke neurology, deep expertise in AI‑driven innovation, and track record of translating research into real‑world impact represent the forward‑thinking perspective that will accelerate NeuroEM's next growth phase.
https://ow.ly/Rqfn50Y6G8X

01/20/2026

Did you know…10 patents covering therapeutic applications, device architecture, emitter design, and treatment protocols provide NeuroEM and its TEMT-RF technology with global coverage and longevity well into the 2030s. That was part of the message our CEO, Chuck Papageorgiou, shared with investors at last week’s PitchForce Early Stage Life Science Conference at J.P. Morgan Healthcare Week.

While at JPM, Chuck spent a day with other Health Transformers at the StartUp Health Apollo House, representing the 's & Brain Health Moonshot on behalf of NeuroEM, a member of the StartUp Health Alzheimer’s Moonshot Community.

01/16/2026

Our TEMT-RF technology is widely applicable, from ’s treatment to wellness.

It is one core technology serving two high-demand markets: clinical, with the potential to reverse cognitive decline and support patient care, and wellness, to enhance cognitive performance and support anti-aging/brain health.

That’s the message CEO Chuck Papageorgiou shared with VC and Angel investors at the PitchForce Early Stage Life Sciences Conference during J.P. Morgan Healthcare Week.

01/13/2026

Today at J.P. Morgan Healthcare Week, CEO Chuck Papageorgiou will present the NeuroEM story to VC and Angel investors at the PitchForce Early Stage Life Science Conference. He'll also demonstrate our groundbreaking -RF technology. https://ow.ly/vWwb50XWhs9

01/13/2026

CEO Chuck Papageorgiou will be among the Health Transformers in the StartUp Health Apollo House today. He represents the 's & Brain Health Moonshot on behalf of NeuroEM, a member of the StartUp Health Alzheimer’s Moonshot Community, and will advance the mission of empowering cognitive health by reversing cognitive decline and promoting lasting wellness through innovations for a brighter future.

Apollo House is an exclusive networking summit during J.P. Morgan Healthcare Week that brings together 500 top founders, funders, and industry leaders to advance Health Moonshots in the Age of . -RF https://ow.ly/tmgP50XWf2U

11/27/2025

Happy Thanksgiving!

11/11/2025

Thanks to all who serve.

11/11/2025

From everyone at NeuroEM, thank you to all who serve.

11/03/2025

Introducing Patty Meagher, our Alzheimer’s Community Advocate who has served as a strategic advisor to NeuroEM in various roles since our earliest days.

Her interest in finding a treatment for the cognitive decline caused by Alzheimer’s is deeply personal–Patty's mother participated in an early safety trial. That experience revealed the potential of our TEMT-RF headset and further inspired her dedication to getting this groundbreaking device into the hands of everyone affected by Alzheimer’s—and anyone interested in maintaining their brain health.

Patty Meagher is a seasoned investor and startup advisor with 20+ years in venture capital and technology. A founding leader in Connecticut’s innovation ecosystem, she’s helped startups raise over $200M and now advocates for Alzheimer’s awareness and innovation.

10/13/2025

"Introducing … NeuroEM’s head of Device R&D Rob Baranowski, who's bringing 30+ years of product design expertise to ensure our groundbreaking TEMT-RF headset for brain health is ready for commercial debut. Early clinical trials show promising results indicating that this device may actually prevent and even reverse cognitive decline associated with aging.

Rob, who led several cellular R&D and design programs at Motorola and Sony, founded Left Coast Engineering in 1999 to develop the first location-aware app. He has since grown LCE’s focus into custom electronic and mechanical product development, supporting more than 250 new products into production with design-for-manufacturability for medical, industrial, commercial and government applications. https://www.linkedin.com/in/lcerob/

10/03/2025

Technology is reshaping how we approach dementia risk reduction.

A new multinational RCT led by Finnish researchers explores a digitally supported multimodal lifestyle intervention for older adults at risk of cognitive decline. The LETHE trial combines in-person sessions with digital tools—smartphones, smartwatches, mobile apps, and even interactive tech like audio glasses and social robots—to personalize care, streamline delivery, and collect digital biomarkers.

As the study authors note, “Digital tools specifically designed for older adults could offer potential for large-scale, cost-effective prevention programs.”

This hybrid model doesn’t just enhance engagement—it generates rich data on usability, adherence, and perceived value, offering insights into how older adults interact with tech in the context of brain health. The trial’s design also opens the door to new hypotheses about early mechanisms of cognitive decline.

For those of us working at the intersection of health IT, aging, and neurodegeneration, this is a compelling signal: scalable, tech-enabled prevention is within reach.

📄 Read the full study on Alzheimer’s Research & Therapy | https://ow.ly/Ky3z50X6tEv